Methods to Predict and Lower the Risk of Prostate Cancer | Zendy

Barbara Ercole | Zendy; Dipen J. Parekh | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Methods to Predict and Lower the Risk of Prostate Cancer

Author(s) -

Barbara Ercole,

Dipen J. Parekh

Publication year - 2011

Publication title -

the scientific world journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.453

H-Index - 93

eISSN - 2356-6140

pISSN - 1537-744X

DOI - 10.1100/tsw.2011.72

Subject(s) - dutasteride , prostate cancer , medicine , oncology , cancer , finasteride , clinical trial , prostate , population , gynecology , urology , environmental health

Chemoprevention for prostate cancer (PCa) continues to generate interest from both physicians and the patient population. The goal of chemoprevention is to stop the malignant transformation of prostate cells into cancer. Multiple studies on different substances ranging from supplements to medical therapy have been undertaken. Thus far, only the studies on 5 alpha-reductase inhibitors (the Prostate Cancer Prevention Trial [PCPT] and Reduction by Dutasteride of Prostate Cancer Events [REDUCE] trial) have demonstrated a reduction in the risk of PCa, while results from the Selenium and Vitamin E Cancer Prevention Trial (SELECT) concluded no decreased risk for PCa with selenium or vitamin E.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research